BECTON DICKINSON & CO shareholders Q3 2023

BECTON DICKINSON & CO's ticker is BDX and the CUSIP is 075887109. A total of 1,515 filers reported holding BECTON DICKINSON & CO in Q3 2023. The put-call ratio across all filers is 0.71 and the average weighting 0.4%.

BECTON DICKINSON & CO shareholders Q3 2023
NameSharesValueWeighting ↓
MCDANIEL TERRY & CO 83,782$21,6602.26%
Garrison Asset Management, LLC 14,205$3,6722.24%
OSTERWEIS CAPITAL MANAGEMENT INC 116,464$30,109,3932.21%
Talisman Wealth Advisors LLC 4,855$1,255,1632.17%
First Fiduciary Investment Counsel, Inc. 35,405$9,1532.15%
Avalon Trust Co 83,684$21,634,8252.14%
TOWER BRIDGE ADVISORS 89,131$23,043,1482.13%
Greystone Financial Group, LLC 32,318$8,355,2422.08%
Long Road Investment Counsel, LLC 16,532$4,2742.07%
KANAWHA CAPITAL MANAGEMENT LLC 82,838$21,416,1082.07%
SeaBridge Investment Advisors LLC 24,132$6,238,8462.06%
GRAYBILL WEALTH MANAGEMENT, LTD. 16,235$4,197,2522.05%
SFE Investment Counsel 27,108$7,008,2482.04%
Private Harbour Investment Management & Counsel, LLC 6,766$1,749,2142.00%
Hamilton Point Investment Advisors, LLC 30,935$7,997,5281.97%
Dempze Nancy E 8,459$2,186,9061.96%
Reynders McVeigh Capital Management, LLC 109,051$28,1931.94%
Birch Capital Management, LLC 11,772$3,043,4151.93%
Fiera Capital Corp 2,306,079$596,190,6051.91%
KAVAR CAPITAL PARTNERS GROUP, LLC 33,742$8,723,3191.89%
About BECTON DICKINSON & CO

Becton Dickinson & Co. (BD) is a global medical technology company that specializes in the development, manufacturing, and sale of medical devices, instrument systems, and reagents. The company is headquartered in Franklin Lakes, New Jersey, and has operations in over 50 countries worldwide.

BD's products are used in a variety of healthcare settings, including hospitals, clinics, laboratories, and blood banks. The company's portfolio includes products for medication management, infection prevention, diagnostic testing, and surgical procedures.

BD has a strong track record of innovation, with a focus on developing products that improve patient outcomes and reduce healthcare costs. The company invests heavily in research and development, with over 2,000 patents and patent applications worldwide.

In recent years, BD has made several strategic acquisitions to expand its product portfolio and geographic reach. In 2017, the company acquired C.R. Bard, a leading provider of medical devices for vascular, urology, and oncology applications. This acquisition has strengthened BD's position in the global medical technology market and is expected to drive long-term growth.

BD has a strong financial position, with a market capitalization of over $70 billion and a dividend yield of 1.3%. The company has a solid track record of revenue growth and profitability, with a five-year revenue growth rate of 6.5% and a net profit margin of 9.5%.

Overall, BD is a well-established and innovative company with a strong position in the global medical technology market. With a focus on improving patient outcomes and reducing healthcare costs, the company is well-positioned for long-term growth and success.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BECTON DICKINSON & CO's shareholders in Q3 2023. To view BECTON DICKINSON & CO's shareholder history, click here.